EQUITY ALERT: The Rosen Law Firm Announces Investigation of Pharmacyclics Inc. Concerning its Proposed Sale to AbbVie Inc. – PCYC

NEW YORK--(BUSINESS WIRE)--

The Rosen Law Firm, P.A., a global investor rights firm, announces that it is investigating the Board of Directors of Pharmacyclics Inc. PCYC for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Pharmacyclics to maximize shareholder value before agreeing to be acquired by AbbVie Inc. ABBV.

If you would like to join the action, go to http://rosenlegal.com/cases-534.html or contact Phillip Kim or Kevin Chan toll-free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com. There is no cost or obligation to you.

Under the terms of the proposed transaction, shareholders may elect to receive $261.25 in cash, AbbVie common stock or a combination for every share of Pharmacyclics they own, subject to proration. The aggregate consideration will consists of approximately 58% cash and 42% AbbVie common stock. The investigation relates to whether the proposal is fair to the public shareholders of Pharmacyclics and whether Pharmacyclics' Board breached its fiduciary duties in connection with the proposed sale.

If you currently own shares of Pharmacyclics and wish to obtain additional information, please visit the website at http://rosenlegal.com/cases-534.html. You may also contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.